AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26225661 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 gastrectomy
Number of subjects: 131
Study 26225661 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall postoperative morbidity
Number of subjects: 131
Study 26225661 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease free survival
Number of subjects: 131
Study 23385553 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D2 40,000 IU per week
Number of subjects: 90
Study 23385553 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D2 20,000 IU per week
Number of subjects: 90
Study 23385553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 20363510 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir (2mg/kg) given twice daily for 5 days
Number of subjects: 452
Study 20363510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 452
Study 20363510 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir (2mg/kg)
Number of subjects: 452
Study 17554248 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea-extract powder supplementation (544 mg polyphenols, 456 mg catechins daily for 2 months)
Number of subjects: 60
Study 17554248 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention for the first 2 months)
Number of subjects: 60
Study 16600720 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat transurethral resection (ReTUR) plus intravesical mitomycin C (MMC)
Number of subjects: 142
Study 16600720 — intervention group
Group type: COMPARATOR
Intervention: Initial transurethral resection (TURB) plus intravesical MMC
Number of subjects: 142
Study 16600720 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat transurethral resection (ReTUR) plus intravesical MMC
Number of subjects: 142
Study 12762258 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 0
Study 12762258 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 14986739 — intervention group
Group type: EXPERIMENTAL
Intervention: Becaplermin (recombinant human platelet-derived growth factor BB)
Number of subjects: 0
Study 14986739 — intervention group
Group type: EXPERIMENTAL
Intervention: DFS-SF (Diabetic Foot Ulcer Scale-Short Form)
Number of subjects: 0
Study 10470338 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of the allelic family MAD20 of MSP1 at day 0
Number of subjects: 81
Study 8599310 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported energy intake from food records (6.98+/‐1.58 MJ/d)
Number of subjects: 29
Study 8599310 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy expenditure measured by the doubly labeled water method (9.00+/‐2.08 MJ/d)
Number of subjects: 29
Study 8599310 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between reported energy intake and expenditure
Number of subjects: 29
Study 1958394 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine 3 x 75 mg
Number of subjects: 17
Study 1958394 — intervention group
Group type: COMPARATOR
Intervention: No Cinnarizine (Control)
Number of subjects: 17
Study 6412638 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg capsule of powdered sodium cromoglycate delivered by turbo inhaler (spinhaler)
Number of subjects: 13
Study 6412638 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of aerosolised sodium cromoglycate delivered by pressurised cannister inhaler (aerosol)
Number of subjects: 13
Study 6412638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31383853 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychopharmacological and psychotherapeutic treatment in MARS study
Number of subjects: 1826
Study 31383853 — intervention group
Group type: EXPERIMENTAL
Intervention: Clustering of MARS discovery sample
Number of subjects: 1826
Study 31383853 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction patterns based on clinical baseline items
Number of subjects: 1826
Study 31383853 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based clustering
Number of subjects: 1826
Study 28626220 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 500 μg subcutaneously every 3 weeks for 24 weeks
Number of subjects: 147
Study 28626220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 28626220 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa during the 48-week open-label period
Number of subjects: 147
Study 27433865 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance therapy (3 sessions weekly for 2 months)
Number of subjects: 52
Study 27433865 — intervention group
Group type: COMPARATOR
Intervention: Self-care treatment advice (control group)
Number of subjects: 52
Study 24210745 — intervention group
Group type: EXPERIMENTAL
Intervention: Action-shooter game
Number of subjects: 81
Study 24210745 — intervention group
Group type: COMPARATOR
Intervention: Racing game
Number of subjects: 81
Study 21943317 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein
Number of subjects: 18
Study 19158002 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol colonoscopy-like preparation
Number of subjects: 116
Study 19158002 — intervention group
Group type: COMPARATOR
Intervention: Traditional liquid diet
Number of subjects: 116
Study 18251251 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial kit based on primer extension
Number of subjects: 0
Study 18251251 — intervention group
Group type: COMPARATOR
Intervention: Subsequent sequencing analysis
Number of subjects: 0
Study 15971459 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive management
Number of subjects: 166
Study 15971459 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 166
Study 11990913 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexanabinol (48 or 150 mg)
Number of subjects: 67
Study 11990913 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 or 3 mL vehicle)
Number of subjects: 67
Study 9641187 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) 4 IU/m2/day for 6 months
Number of subjects: 20
Study 9641187 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 8120654 — intervention group
Group type: COMPARATOR
Intervention: Low fiber diet (15 g total dietary fiber/d)
Number of subjects: 10
Study 8120654 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet supplemented with 62 g/d of brewer's spent grain
Number of subjects: 10
Study 2929483 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated soy-protein-based formula with added carnitine
Number of subjects: 0
Study 2929483 — intervention group
Group type: COMPARATOR
Intervention: Isolated soy-protein-based formula without added carnitine (control)
Number of subjects: 0
Study 947448 — intervention group
Group type: EXPERIMENTAL
Intervention: Specially designed stretcher suspension system
Number of subjects: 0
Study 947448 — intervention group
Group type: COMPARATOR
Intervention: Purpose-built ambulance
Number of subjects: 0
Study 31919523 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-magnitude contingency management (CM-H)
Number of subjects: 161
Study 31919523 — intervention group
Group type: COMPARATOR
Intervention: Low-magnitude contingency management (CM-L)
Number of subjects: 161
Study 29944915 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaming group (3D first-person shooter)
Number of subjects: 29
Study 27121777 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline RA scores and follow-up assessments
Number of subjects: 512
Study 27121777 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline erosions, female gender, better mental health, lower DAS28-P
Number of subjects: 512
Study 27121777 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline OST scores
Number of subjects: 512
Study 27121777 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hand OA
Number of subjects: 512
Study 27121777 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory disease activity
Number of subjects: 512
Study 25687900 — intervention group
Group type: EXPERIMENTAL
Intervention: Men's Safer Sex (MenSS) website
Number of subjects: 166
Study 25687900 — intervention group
Group type: COMPARATOR
Intervention: Usual sexual health clinical care
Number of subjects: 166
Study 23945447 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (30 mg/d, 50 mg/d, or 70 mg/d)
Number of subjects: 161
Study 23945447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 20102786 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (cholinergic antagonist)
Number of subjects: 0
Study 20102786 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological-induced menopause (GnRHa treatment)
Number of subjects: 0
Study 18069117 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoselective vaporization of the prostate (PVP)
Number of subjects: 125
Study 18069117 — intervention group
Group type: COMPARATOR
Intervention: Open prostatectomy (OP)
Number of subjects: 125
Study 18069117 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PVP and OP
Number of subjects: 125
Study 16504462 — intervention group
Group type: EXPERIMENTAL
Intervention: Spider phobics
Number of subjects: 50
Study 16504462 — intervention group
Group type: COMPARATOR
Intervention: Nonphobics
Number of subjects: 50
Study 16504462 — intervention group
Group type: EXPERIMENTAL
Intervention: Spider phobics and nonphobics
Number of subjects: 50
Study 12941030 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 1379
Study 12941030 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulants (OA)
Number of subjects: 1379
Study 11524494 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA)
Number of subjects: 239
Study 11524494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 9301385 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural anaesthesia
Number of subjects: 31
Study 9301385 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 31
Study 8300811 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone 12 IU/day
Number of subjects: 42
Study 8300811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 3570862 — intervention group
Group type: EXPERIMENTAL
Intervention: 650 micrograms daily vitamin A supplement
Number of subjects: 0
Study 2568777 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 ml iopromide/kg body weight
Number of subjects: 0
Study 2568777 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 ml iopromide/kg body weight
Number of subjects: 0
Study 2568777 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 ml iopromide/kg body weight
Number of subjects: 0
Study 2568777 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 ml iopromide/kg body weight
Number of subjects: 0
Study 31430058 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC) for 1 year
Number of subjects: 97
Study 31430058 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) for 2 years
Number of subjects: 97
Study 31742796 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive program (CBT-based, telepsychology-delivered)
Number of subjects: 46
Study 31742796 — intervention group
Group type: COMPARATOR
Intervention: Active control (psychoeducational website)
Number of subjects: 46
Study 28265880 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine administration
Number of subjects: 0
Study 25043482 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 44
Study 25043482 — intervention group
Group type: COMPARATOR
Intervention: Health promotion
Number of subjects: 44
Study 25043482 — intervention group
Group type: COMPARATOR
Intervention: Participation‐centered course
Number of subjects: 44
Study 23833309 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (200 mg/m(2)/d) plus cisplatin (75 mg/m(2))
Number of subjects: 189
Study 23833309 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IFN-α2b (HDI)
Number of subjects: 189
Study 23833309 — intervention group
Group type: COMPARATOR
Intervention: Observation (surgery alone)
Number of subjects: 189
Study 21824454 — intervention group
Group type: EXPERIMENTAL
Intervention: lisdexamfetamine
Number of subjects: 831
Study 21824454 — intervention group
Group type: EXPERIMENTAL
Intervention: triple‐bead mixed amphetamine salts (MAS)
Number of subjects: 831
Study 21824454 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 831
Study 19853815 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy intervention of lavender and ginger essential oils
Number of subjects: 94
Study 19853815 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention of jojoba oil
Number of subjects: 94
Study 16755435 — intervention group
Group type: EXPERIMENTAL
Intervention: MBO model of treatment (experimental group U[+])
Number of subjects: 494
Study 16755435 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical treatment (control group K[+])
Number of subjects: 494
Study 16755435 — intervention group
Group type: EXPERIMENTAL
Intervention: MBO(+) patients
Number of subjects: 494
Study 16755435 — intervention group
Group type: EXPERIMENTAL
Intervention: Both experimental groups (U[+], U[−])
Number of subjects: 494
Study 12692663 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (self-transcendence support group)
Number of subjects: 39
Study 12692663 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (non-participants)
Number of subjects: 39
Study 10474470 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 60% DMSO applied before each filling session
Number of subjects: 40
Study 10474470 — intervention group
Group type: COMPARATOR
Intervention: Traditional tissue expansion
Number of subjects: 40
Study 8627841 — intervention group
Group type: EXPERIMENTAL
Intervention: High ligation of the internal spermatic vein
Number of subjects: 85
Study 8627841 — intervention group
Group type: COMPARATOR
Intervention: Followed without any treatment
Number of subjects: 85
Study 1763406 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (7.5 Gy point A dose)
Number of subjects: 138
Study 1763406 — intervention group
Group type: COMPARATOR
Intervention: Group B (6 Gy point A dose)
Number of subjects: 138
Study 6283076 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold therapy
Number of subjects: 0
Study 31380605 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard hemodialysis (HD) with a polysulfone membrane
Number of subjects: 155
Study 31380605 — intervention group
Group type: COMPARATOR
Intervention: Predilution hemodiafiltration (HDF) with the same polysulfone membrane
Number of subjects: 155
Study 28394361 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut oil (15 cc daily for 90 days)
Number of subjects: 100
Study 26559870 — intervention group
Group type: EXPERIMENTAL
Intervention: Students with ptosis
Number of subjects: 4106
Study 26559870 — intervention group
Group type: COMPARATOR
Intervention: Students without ptosis
Number of subjects: 4106
Study 26559870 — intervention group
Group type: EXPERIMENTAL
Intervention: Students with bilateral ptosis
Number of subjects: 4106
Study 26559870 — intervention group
Group type: EXPERIMENTAL
Intervention: Ptotic eyes
Number of subjects: 4106
Study 26559870 — intervention group
Group type: COMPARATOR
Intervention: Non-ptotic eyes
Number of subjects: 4106
Study 23417731 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative QI intervention
Number of subjects: 12
Study 23417731 — intervention group
Group type: COMPARATOR
Intervention: Existing communication structure
Number of subjects: 12
Study 21704493 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (480 mg)
Number of subjects: 16
Study 21704493 — intervention group
Group type: COMPARATOR
Intervention: Sham (24 mg)
Number of subjects: 16
Study 19222109 — intervention group
Group type: EXPERIMENTAL
Intervention: DG + KH group
Number of subjects: 151
Study 19222109 — intervention group
Group type: COMPARATOR
Intervention: MT group
Number of subjects: 151
Study 19222109 — intervention group
Group type: COMPARATOR
Intervention: DG group
Number of subjects: 151
Study 19222109 — intervention group
Group type: EXPERIMENTAL
Intervention: MT + KH group
Number of subjects: 151
Study 16547328 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ciclosporin A 0.05%
Number of subjects: 40
Study 16547328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 14723265 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 0
Study 14723265 — intervention group
Group type: COMPARATOR
Intervention: Conventional antiepileptic agents (phenytoin, phenobarbital, carbamazepine, valproic acid)
Number of subjects: 0
Study 11232180 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy for severe acute alcoholic hepatitis
Number of subjects: 0
Study 8694204 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 81
Study 8694204 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 81
Study 8694204 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane and Halothane
Number of subjects: 81
Study 1597912 — intervention group
Group type: EXPERIMENTAL
Intervention: Betacarotene as a possible skin cancer preventive agent
Number of subjects: 1805
Study 1597912 — intervention group
Group type: COMPARATOR
Intervention: Current smokers
Number of subjects: 1805
Study 1597912 — intervention group
Group type: COMPARATOR
Intervention: Former smokers
Number of subjects: 1805
Study 1597912 — intervention group
Group type: COMPARATOR
Intervention: Heavy smokers
Number of subjects: 1805
Study 6689670 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid mixture (L‐phenylalanine, L‐tryptophan) infused intraduodenally at increasing rates (0.2, 0.8, and 3.2 ml X min‐1)
Number of subjects: 8
Study 6689670 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline infused into the intestine at increasing rates (0.2, 0.8, and 3.2 ml X min‐1)
Number of subjects: 8
Study 6689670 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol solutions of increasing osmolality (370, 520, and 700 mosmol X kg‐1) infused into the duodenum at 0.2 ml X min‐1
Number of subjects: 8
Study 6689670 — intervention group
Group type: COMPARATOR
Intervention: Atropine infusion (20 micrograms X kg‐1 X h‐1)
Number of subjects: 8
Study 31483549 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive outreach intervention (mailed invitation and telephone calls, free cessation treatment including nicotine replacement therapy and intensive telephone counseling)
Number of subjects: 2406
Study 31483549 — intervention group
Group type: COMPARATOR
Intervention: Usual care (access to a primary care physician, insurance coverage of FDA-approved smoking cessation medications, and the state's telephone quitline)
Number of subjects: 2406
Study 31483549 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive outreach intervention
Number of subjects: 2406
Study 30004139 — intervention group
Group type: EXPERIMENTAL
Intervention: MOUTh (Managing Oral Hygiene Using Threat Reduction)
Number of subjects: 101
Study 30004139 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study 27770740 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 194
Study 27770740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 25414155 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (0.6 mg single dose, titrated to 1.8 mg after 21 days)
Number of subjects: 0
Study 25414155 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0
Study 25414155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23080427 — intervention group
Group type: EXPERIMENTAL
Intervention: ProDisc-C
Number of subjects: 209
Study 23080427 — intervention group
Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 209
Study 20206556 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% polidocanol foam
Number of subjects: 143
Study 20206556 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% polidocanol foam
Number of subjects: 143
Study 16446126 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative expiratory pressure (NEP) at 5hPa
Number of subjects: 8
Study 16446126 — intervention group
Group type: COMPARATOR
Intervention: Control (no NEP)
Number of subjects: 8
Study 12899648 — intervention group
Group type: EXPERIMENTAL
Intervention: PolyHeme
Number of subjects: 20
Study 12899648 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 11187059 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 9424967 — intervention group
Group type: COMPARATOR
Intervention: Psychological treatment (Group I)
Number of subjects: 40
Study 9424967 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.2 mg/kg orally (Group II)
Number of subjects: 40
Study 8462805 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate mesilate (4 g per day intravenously for 7 days)
Number of subjects: 223
Study 8462805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 3517742 — intervention group
Group type: EXPERIMENTAL
Intervention: PhEA 34c (1.9% sodium hyaluronate)
Number of subjects: 15
Study 3517742 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (BSS)
Number of subjects: 15
Study 30238574 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetazolamide at a dose of 500 mg once daily
Number of subjects: 519
Study 30238574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519
Study 26504153 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (1000 mg) plus prednisone (5 mg)
Number of subjects: 297
Study 26504153 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (1000 mg) plus exemestane (25 mg)
Number of subjects: 297
Study 26504153 — intervention group
Group type: COMPARATOR
Intervention: Exemestane (25 mg)
Number of subjects: 297
Study 26504153 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus exemestane (AAE)
Number of subjects: 297
Study 26098476 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 LCPUFA (1.2 g EPA/DHA/day), n=85
Number of subjects: 126
Study 26098476 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil), n=41
Number of subjects: 126